Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
Pfizer
NextCure, Inc.
Genmab
OncoNano Medicine, Inc.
Herlev Hospital
Incyte Corporation
Pfizer
Seagen Inc.
Seagen Inc.
Eli Lilly and Company
Incyte Corporation
Eisai Inc.
Daiichi Sankyo
INSYS Therapeutics Inc